Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

Bullfinch May. 13 at 8:24 PM

$VTVT https://ir.vtvtherapeutics.com/sec-filings/sec-filing/8-k/0001641489-26-000019

0 · Reply

Bullfinch May. 13 at 8:12 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-reports-first-quarter-2026-financial-results

0 · Reply

km1663 May. 13 at 8:12 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-reports-first-quarter-2026-financial-results

0 · Reply

dcajic2 May. 12 at 7:42 PM

$VTVT why do people say bullish now? They still Have many months before any News. How if the news isn’t positive?

0 · Reply

WallStreetVice May. 12 at 5:34 PM

$VTVT

0 · Reply

WallStreetVice May. 12 at 5:25 PM

$VTVT Lfg

0 · Reply

GDS_investing May. 12 at 4:30 PM

$VTVT yes all in

0 · Reply

GDS_investing May. 12 at 3:11 PM

$VTVT long 44 then 56 and 84$ long

0 · Reply

LongBallBarn May. 12 at 2:24 PM

$VTVT alive

0 · Reply

SuperGreenToday May. 12 at 2:11 PM

$VTVT

0 · Reply

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026, 4:15 PM EDT - 5 days ago

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026, 8:00 AM EDT - 6 days ago

vTv Therapeutics to Participate in Upcoming May Investor Conferences

Mar 16, 2026, 8:00 AM EDT - 2 months ago

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

2026-03-12T10:46:05.000Z - 2 months ago

vTv Therapeutics initiated with an Outperform at Evercore ISI

2026-03-11T11:11:56.000Z - 2 months ago

vTv Therapeutics price target raised to $55 from $35 at Alliance Global

2026-03-10T20:11:02.000Z - 2 months ago

vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)

Mar 10, 2026, 4:01 PM EDT - 2 months ago

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 13, 2026, 8:00 AM EST - 3 months ago

vTv Therapeutics to Participate in Upcoming Investor Conferences

2026-02-02T13:15:17.000Z - 3 months ago

vTv Therapeutics expanded its license agreement with Newsoara Biopharma

Feb 2, 2026, 8:00 AM EST - 3 months ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

2026-01-27T12:25:32.000Z - 3 months ago

vTv Therapeutics price target raised to $49 from $40 at BTIG

2026-01-22T21:11:50.000Z - 3 months ago

vTv Therapeutics initiated with a Buy at Roth Capital

2026-01-05T10:50:07.000Z - 4 months ago

vTv Therapeutics initiated with a Buy at TD Cowen

2025-12-19T13:20:18.000Z - 5 months ago

vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright

2025-12-18T21:10:54.000Z - 5 months ago

vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi

Dec 18, 2025, 4:05 PM EST - 5 months ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

2025-11-18T21:20:58.000Z - 6 months ago

vTv Therapeutics initiated with a Buy at BTIG

2025-11-06T22:30:59.000Z - 6 months ago

vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)

Nov 6, 2025, 4:15 PM EST - 6 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-05T14:42:37.000Z - 6 months ago

vTv Therapeutics trading resumes

2025-11-05T14:36:57.000Z - 6 months ago

vTv Therapeutics trading halted, volatility trading pause

2025-10-09T12:11:55.000Z - 7 months ago

vTv Therapeutics announces three appointments to Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 7 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

2025-10-03T20:45:20.000Z - 7 months ago

vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders

2025-09-17T14:00:38.000Z - 8 months ago

vTv Therapeutics trading resumes

2025-09-17T13:55:25.000Z - 8 months ago

vTv Therapeutics trading halted, volatility trading pause

Sep 15, 2025, 8:00 AM EDT - 8 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 3, 2025, 4:57 PM EDT - 8 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

2025-09-02T12:30:44.000Z - 9 months ago

vTv Therapeutics announces $80M private placement

Sep 2, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Aug 12, 2025, 4:15 PM EDT - 9 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-08-11T12:20:35.000Z - 9 months ago

vTv Therapeutics announces USPTO allowance of patent covering cadisegliatin

Aug 11, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

2025-08-07T12:30:56.000Z - 9 months ago

vTv Therapeutics announces first participant randomized in CATT1 Phase 3 trial

Aug 7, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Jun 11, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 1 year ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 1 year ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 8:30 AM EDT - 1 year ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 3 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Bullfinch May. 13 at 8:24 PM

$VTVT https://ir.vtvtherapeutics.com/sec-filings/sec-filing/8-k/0001641489-26-000019

0 · Reply

Bullfinch May. 13 at 8:12 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-reports-first-quarter-2026-financial-results

0 · Reply

km1663 May. 13 at 8:12 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-reports-first-quarter-2026-financial-results

0 · Reply

dcajic2 May. 12 at 7:42 PM

$VTVT why do people say bullish now? They still Have many months before any News. How if the news isn’t positive?

0 · Reply

WallStreetVice May. 12 at 5:34 PM

$VTVT

0 · Reply

WallStreetVice May. 12 at 5:25 PM

$VTVT Lfg

0 · Reply

GDS_investing May. 12 at 4:30 PM

$VTVT yes all in

0 · Reply

GDS_investing May. 12 at 3:11 PM

$VTVT long 44 then 56 and 84$ long

0 · Reply

LongBallBarn May. 12 at 2:24 PM

$VTVT alive

0 · Reply

SuperGreenToday May. 12 at 2:11 PM

$VTVT

0 · Reply

dcajic2 May. 12 at 1:57 PM

$VTVT I still think under $30 before rising. Shorting still. Reality is no news is expected for many months and with this company news rarely comes.

0 · Reply

CoffeeRocks May. 12 at 11:09 AM

$BTAI $CNS $ANVS $VTVT $IMUX

0 · Reply

GDS_investing May. 11 at 5:55 PM

$VTVT Don't sell a diamond for the price of glass Buy it! any price under 40$ is a gift imo

0 · Reply

Bullfinch May. 8 at 8:16 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-inducement-grants-under-nasdaq-0

0 · Reply

GDS_investing May. 8 at 4:49 PM

$VTVT I added 100 more shares LONG AND STRONG any price under 40 is a gift imo watch $SNDK $MU $AMD $SOXL long $VTVT

0 · Reply

GDS_investing May. 8 at 4:22 PM

$VTVT vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May:

0 · Reply

GDS_investing May. 8 at 4:19 PM

$VTVT long

0 · Reply

dcajic2 May. 7 at 6:43 PM

$VTVT Still months away from having any news. Why would anyone go long yet. Under $30 would be a much better entry.

0 · Reply

Bullfinch May. 7 at 3:05 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-participate-upcoming-may-investor-conferences

0 · Reply

ALLEGEDLY01 May. 6 at 8:07 PM

$GCTK TA + Speculation = a powerful trader In the speculation category we have a history of trading $VTVT actually as one of my first memorable successful swings. Do your research this thing is about to run wild

0 · Reply

dcajic2 May. 4 at 7:03 PM

$VTVT Interest waning. Arill On the before any news drop. Could easily fall below $30

0 · Reply

BillionerOfKing May. 1 at 4:14 AM

$VTVT Current Stock Price: $32.27

0 · Reply

Market Cap	119.98M
Revenue (ttm)	0.00
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	42,977
Avg Vol	59,588
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	64%
Beta	0.26
Analysts	Strong Sell
Price Target	$53.33